[A23-34] Deucravacitinib (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V
Last updated 17.07.2023
Project no.:
A23-34
Commission:
Commission awarded on 17.04.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Skin and hair
Indication:
Adult patients with moderate to severe plaque psoriasis
Result of dossier assessment:
- Patients who are not candidates for conventional treatment in the context of initial systemic therapy: added benefit not proven
- Patients who have responded inadequately or who have been intolerant to systemic therapy: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.